Cesare Gridelli

Author PubWeight™ 13.21^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.	Oncology (Williston Park)	2010	2.06
2	Treatment of pulmonary neuroendocrine tumours: state of the art and future developments.	Cancer Treat Rev	2012	1.37
3	Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.	J Thorac Oncol	2007	1.07
4	Lung cancer in the elderly.	J Clin Oncol	2007	1.00
5	Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies.	J Clin Oncol	2007	0.99
6	Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.	Oncologist	2009	0.97
7	Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.	J Thorac Oncol	2007	0.93
8	Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.	J Thorac Oncol	2007	0.89
9	A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.	Clin Lung Cancer	2007	0.87
10	Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.	Clin Lung Cancer	2012	0.85
11	Targeted therapies and non-small-cell lung cancer: new developments.	Curr Opin Oncol	2007	0.82
12	Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics.	Drugs Aging	2004	0.77
13	Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road.	Curr Opin Oncol	2008	0.75
14	New insights in drug development for the non-small cell lung cancer therapy.	Front Biosci	2008	0.75